North West Reading CCG News

Freestyle Libre statement


FreeStyle Libre® is a form of “continuous flash glucose monitoring”, with glucose readings provided by scanning a sensor. It was the first of these technologies to be added to the national Drug Tariff on 1 November 2017. It is important to note that the Drug Tariff is not a list of recommended products and NHS organisations and prescribers are not obligated to supply every item listed within it.

Following a meeting of our GP Medicines Optimisation Committee on Wednesday 21st February 2018 where the glucose monitoring device Freestyle Libre was discussed, Berkshire West Clinical Commissioning Groups have agreed to undertake an evaluation study involving 50 patients. During this evaluation we will assess which groups of patients benefit most from the device. This work will be undertaken with the Specialist Diabetes Team at the Royal Berkshire NHS Foundation Trust.

 – ENDS –

For further media information please email:


Four Berkshire West CCGs set to merge on 1st Apri...
Pain patients' hospital wait reduced by 90% saving...
Top Top